跳到正文
原文
Nature Medicine· Rodabe N. Amaria·· 17 天前AI 评分50

可调节膜结合IL-15工程TIL细胞疗法治疗免疫检查点抑制剂耐药晚期黑色素瘤:1期和1/2期试验的汇总分析

Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials

AI 导读

amsokigene autoleucel在两项试验中成功制造并表现出良好的耐受性,初步显示了对免疫检查点抑制剂耐药黑色素瘤患者的临床疗效信号。

正文

Nature Medicine, Published online: 03 November 2026; doi:10.1038/s41591-026-04743-6

As presented at the Society for Immunotherapy of Cancer 2026 Annual Meeting, in a non-prespecified pooled analysis of two trials, amsokigene autoleucel, an autologous tumor-infiltrating lymphocyte therapy engineered to eliminate the need for IL-2, was successfully manufactured and well tolerated and showed a preliminary clinical efficacy signal in patients with immune checkpoint inhibitor-refractory melanoma.

来源:Nature Medicine · nature.com